Minerva Neurosciences (NASDAQ:NERV) Given “Neutral” Rating at HC Wainwright

HC Wainwright restated their neutral rating on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $5.00 price objective on the biopharmaceutical company’s stock.

Separately, StockNews.com initiated coverage on Minerva Neurosciences in a research report on Saturday, November 2nd. They issued a “sell” rating on the stock.

Minerva Neurosciences Price Performance

NASDAQ NERV opened at $2.31 on Wednesday. The stock’s fifty day moving average price is $2.64 and its 200 day moving average price is $2.79. Minerva Neurosciences has a 1 year low of $2.26 and a 1 year high of $13.49. The company has a market cap of $16.15 million, a price-to-earnings ratio of -0.52 and a beta of 0.18.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). Research analysts expect that Minerva Neurosciences will post -2.26 earnings per share for the current year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.